Targeting Impairment of Erection and Sexual Function

The medication is commonly used to help with addressing erectile dysfunction (ED), a condition where men experience difficulty getting or keeping an erection. The primary indications include erectile difficulty and Pulmonary Arterial Hypertension (PAH). This is relevant for easing ED that may be associated with complex conditions like diabetes or arise after certain surgical procedures. It provides a supportive benefit that facilitates the necessary physiological response, which supports patients during episodes of heightened discomfort and assists with maintaining functional stability.

---

Relief for Functional Limitations in Pulmonary Arterial Hypertension

The medication is considered relevant across therapeutic domains involving cardiovascular and pulmonary stress, specifically for PAH. It may assist with addressing symptom clusters that include shortness of breath and fatigue associated with the condition. This therapeutic support is applicable to adults and children (aged 1 year and older) with PAH. When applied during phases when symptoms become more noticeable, it contributes to easing the overall symptom load and supports general well-being by contributing to improved comfort during periods of physical activity.

---

Quick Fact: Relief for Pulmonary Vascular Distress

The medication supports general well-being by contributing to improved comfort during periods of physical activity.

Regulatory References

1. NIH MedlinePlus Drug Information

Davigor (Sildenafil) eligibility is defined by official regulatory labeling, with strict exclusions for certain populations and health conditions.

Contraindicated Populations (Prohibited Use)

Use of Davigor is absolutely contraindicated in patients taking organic nitrates in any form (regularly or intermittently) or nitric oxide donors due to the severe risk of hypotension. It is also contraindicated in patients using the guanylate cyclase stimulator riociguat or those with a known hypersensitivity to sildenafil.

Formal exclusions also apply to patients with a history of vision loss due to Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION), those with severe hepatic impairment, severe hypotension ( BP < 90/50 mmHg), a recent history of stroke or myocardial infarction, or known hereditary degenerative retinal disorders.

Age and Condition Restrictions

Population Group	Eligibility Status
Adult Men (ED)	Approved for use.
Women	Not indicated for the treatment of erectile dysfunction.
Pediatrics (<18 years)	Not indicated for erectile dysfunction. For Pulmonary Arterial Hypertension (PAH), use is approved for children 1 year and older, but regulatory warnings exist regarding potential increased mortality with higher doses, leading to a not recommended status by some authorities.
Severe Renal/Hepatic Impairment	Severe hepatic impairment is contraindicated. For severe renal impairment ( CL cr < 30 mL/min), restricted use may apply.

Caution is advised for men for whom sexual activity is inadvisable due to cardiovascular status and in patients with conditions predisposing to priapism (e.g., anatomical penile deformation or sickle cell anemia).

Davigor (lemborexant) interacts with several classes of medicines and products primarily through two main mechanisms documented in regulatory sources: its metabolism and its effect on the central nervous system (CNS).

Interactions Affecting Davigor Levels

Davigor is a substrate of the CYP3A4 enzyme, and its levels can be significantly altered by medicines that change the activity of this enzyme. These are summarized as follows:

Interacting Product Category	Official Regulatory Constraint
Strong CYP3A Inhibitors (e.g., itraconazole, clarithromycin, certain HIV medicines)	Co-administration is generally to be avoided.
Moderate CYP3A Inhibitors (e.g., fluconazole, verapamil)	Dosage adjustment is required, with a maximum dose specified.
Strong or Moderate CYP3A Inducers (e.g., rifampin, carbamazepine, St. John’s wort)	Co-administration is generally to be avoided due to decreased effectiveness.

Interactions Causing Additive CNS Effects

Concomitant use with other CNS depressants, including alcohol, opioids, benzodiazepines (e.g., lorazepam, clonazepam), tricyclic antidepressants, and other sleep medications (e.g., zolpidem, eszopiclone), may result in potentially additive impairment. Official warnings advise patients not to consume alcohol and recommend that dosage adjustments of both Davigor and the co-administered CNS depressant may be necessary due to this pharmacodynamic effect. The use of Davigor with grapefruit or grapefruit juice is also not recommended.

The mechanism of Davigor centers on a specific approach to modulating the brain's central sleep-wake cycle by acting on the orexin neuropeptide system. This system plays a crucial role in maintaining wakefulness and arousal.

Dual Antagonism of Wakefulness Receptors

Davigor functions as a dual competitive antagonist, engaging the OX1 and OX2 orexin receptors in the brain. By binding to these specific targets, the drug blocks the wake-promoting orexin signaling molecules from activating their receptors. This action directly suppresses the neural drive that promotes wakefulness.

Modulating the Sleep-Wake Balance

The suppression of the wakefulness drive allows the body's natural sleep-promoting mechanisms to become dominant. This shift in the central nervous system's signaling balance enables the progression from the state of wakefulness to the state of sleep and contributes to the duration of the sleep state. The resulting physiological effect is a lowered activity of arousal signals throughout the night.

Davigor (Sildenafil) is administered primarily via the oral route, available as film-coated tablets and, for specific use in pulmonary arterial hypertension (PAH), as a reconstituted oral suspension. An intravenous (IV) injection formulation is available for PAH patients who are temporarily unable to take the medicine by mouth.

---

The administration schedule for Sildenafil is defined by two distinct use patterns. For erectile dysfunction (ED), the medicine is taken as needed, typically 30 minutes to 4 hours before activity, with a maximum frequency of once per day. The usual starting oral dose for adults is 50 mg, which may be adjusted within a range of 25 mg to 100 mg.

In the context of PAH, the administration follows a routine schedule of three times a day (TID), with doses taken approximately 4 to 8 hours apart. The standard dose in this maintenance regimen is 20 mg, and this may be titrated up to a maximum dose of 80 mg three times daily, based on patient tolerability.

Standard administration guidelines specify that the oral tablet may be taken with or without food; however, consuming it with a high-fat meal is noted to delay the rate of absorption. A lower starting oral dose of 25 mg is generally considered necessary for older adults (65 years and over), as well as for individuals with severe hepatic or renal impairment. This lower starting dose is also required when the medicine is co-administered with certain strong CYP3A4 inhibitors or alpha-blockers, to adhere to specific administration constraints.

Research evidence / Overview of studies for Davigor

Research has explored Davigor in several contexts, focusing on conditions where symptoms may vary in intensity. Studies help show what has been observed so far, but it's important to remember that findings describe group patterns, not personal outcomes. Research does not determine whether an individual will respond similarly.

Davigor in conditions characterized by fluctuating or episodic manifestations

Davigor was studied for its use in conditions characterized by fluctuating or episodic manifestations. These studies were used in research exploring how symptoms change over time and were relevant in trials assessing short-term or episodic symptom patterns. The evidence gathered in these contexts focused on outcomes related to physical discomfort and outcomes describing episodic or acute changes.

The findings describe patterns observed in the studied populations, and research suggests that certain measured changes was associated with the use of Davigor during the study period. However, the evidence is limited, and certainty remains low regarding the full scope of these findings. It is noted that the results apply only to the specific populations studied, and there is limited information for long-term outcomes.

Davigor in conditions involving periods of heightened symptoms

Research examined Davigor in conditions involving periods of heightened symptoms, often applied in research contexts involving fluctuating or unstable symptoms. These studies monitored outcomes linked to inflammatory or irritative states and outcomes reflecting daily functioning or activity level. Studies were conducted during research scenarios exploring short-term symptom changes.

Data show patterns related to how symptoms evolved in the observed populations. Research highlights changes measured during the study period, helping to contextualize what patients reported during episodes where symptoms become more noticeable. While these patterns was observed in some studies, comparative evidence is lacking, and the certainty around these findings remains low. Long-term effects are not fully established, and this area requires more comprehensive research.

Davigor in conditions marked by functional limitations

Davigor was evaluated in conditions marked by functional limitations, with studies monitoring patient-reported outcomes describing perceived discomfort. Research explored short-term symptom changes and applied in studies examining patient-reported experiences over defined time intervals.

Findings indicate patterns related to perceived discomfort and provide context regarding temporary physiological imbalance. However, research exploring this specific area is ongoing, and the sample sizes were modest across several evaluations. Evidence quality varies across studies, and data for certain groups remain insufficient. Subgroup findings are uncertain, which means results for specific patient types remain less clear.

Key Studies & References Sildenafil - StatPearls - NCBI Bookshelf.

Common questions about Davigor (FAQ)

---

Q: How long does it usually take for Davigor to start working?

The medicine typically begins to work within 30 to 60 minutes for use in erectile dysfunction (ED). For this condition, the administration window allows for use in advance of activity. When used for pulmonary arterial hypertension (PAH), the maximum effect on blood pressure is usually observed within one to two hours.

Q: How long does Davigor stay in my system after I stop taking it?

Official product information notes that the medicine is generally cleared from the body within about a day after the last dose. This is based on its terminal half-life, which is approximately four hours.

Q: What if I take Davigor and don't notice any changes?

Regulatory documents state that the prescribed dose may be adjusted based on how well the medicine works and how it is tolerated. For erectile dysfunction, the dose can be increased up to a maximum if the current dose is not effective. If a patient does not notice changes, consultation with a healthcare professional is indicated.

Q: What happens if I miss a scheduled time to take Davigor?

If a patient is taking Davigor for pulmonary arterial hypertension (PAH) on a regular schedule and misses a dose, official guidance typically suggests taking the missed dose as soon as it is remembered. However, if it is almost time for the next scheduled dose, official instruction is to skip the missed dose and return to the regular schedule. Guidance also typically cautions against taking a double dose to compensate for a missed one.

Q: Can I stop taking Davigor suddenly, or do I need to taper off?

The medicine is used as needed for erectile dysfunction, which inherently does not require a tapering schedule. For the routine schedule used in pulmonary arterial hypertension (PAH), regulatory documents do not specify a tapering process. Any decision to stop or change the routine frequency of use is typically handled through consultation with a healthcare professional.

Q: Can Davigor be crushed or broken if someone has trouble swallowing pills?

Davigor is manufactured as an oral, film-coated tablet. In general, film-coated tablets should not be altered unless the official guidance explicitly directs it. An oral suspension formulation is available for use in PAH, which provides an alternative for individuals who have difficulty swallowing tablets.

Q: Is it okay to take Davigor while operating machinery?

Official warnings advise patients to be aware of how they react to Davigor before driving or operating machinery. This caution is due to the risk of side effects such as dizziness and temporary visual disturbances that have been associated with the medication.

Q: Can Davigor be used during pregnancy or while breastfeeding?

The FDA label notes that insufficient data are available to inform a drug-related risk during pregnancy when used for PAH. The medicine is known to be excreted into human milk at very low levels, and the clinical need and potential effects on the breastfed infant should be assessed by a healthcare professional.

Q: Can older adults use Davigor safely?

Davigor is approved for use in older adults. Regulatory labeling advises a lower starting oral dose for individuals aged 65 and over. This recommendation is based on typically higher plasma concentrations observed in this population.

Q: Is there a link between Davigor and mood changes?

Official adverse reaction lists classify anxiety as a common side effect of the medicine (occurring in 1% to 10% of patients). Furthermore, regulatory documents have noted reports of depression and abnormal dreams with an unspecified frequency.

Q: What should I do if the side effects feel too strong?

Regulatory guidance indicates that follow-up with a healthcare professional is necessary if a patient experiences side effects that are severe or persist. For rare, serious reactions like a prolonged erection (Priapism) or sudden loss of vision, official documents classify the need for immediate medical attention in such events.

Q: Does Davigor affect sleep patterns?

Official adverse reaction reports list insomnia (difficulty sleeping) and anxiety as common side effects of the medication (occurring in 1% to 10% of patients). Sleepiness or drowsiness has also been noted in postmarketing reports.

Q: Is Davigor known to cause weight gain or weight loss?

Official regulatory documents have noted that increased weight and fluid retention are uncommon side effects (occurring in less than 10% of patients) that have been observed in certain clinical trials involving Sildenafil.

Q: What is the difference between a side effect and an interaction?

In regulatory documents, a side effect (or adverse reaction) describes an unintended and undesirable physical or mental effect of the drug itself that occurs during treatment. An interaction is defined as a change in the drug's effect when it is combined with another substance or medicine, often due to additive effects or changes in metabolism.

Q: Are there different strengths or formulations of Davigor?

Yes, Davigor (Sildenafil) is available in multiple tablet strengths, typically including 25 mg, 50 mg, and 100 mg for erectile dysfunction, and 20 mg for pulmonary arterial hypertension (PAH). In addition to the oral tablets, an oral suspension and an intravenous (IV) injection formulation are also approved for use in PAH.

Q: Is Davigor available as a generic medicine?

Yes, Davigor contains the active ingredient Sildenafil, which is widely available as a generic medicine.

Q: Does the efficacy of Davigor vary based on patient characteristics?

Official documents note that a lower starting dose is recommended for specific patient characteristics, such as older adults and patients with severe liver or kidney problems. This is because these characteristics can affect how the body processes the medicine, which may influence its concentration and overall effect.

Q: How should Davigor be stored at home?

Official labeling requires that Davigor be stored at controlled room temperature, typically 20 C to 25 C. The medicine must be kept in its original container, tightly closed, and protected from excessive moisture. There is no explicit regulatory instruction to protect the tablets from light.

Official Storage and Handling Requirements

Davigor (Sildenafil tablets) must be stored strictly according to the conditions defined in regulatory labeling to maintain product stability. The required storage environment is controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F). The medication must be kept in the original container it came in and the container must be kept tightly closed to provide protection from excessive heat and moisture.

Child Safety and Disposal

A critical regulatory requirement is that Davigor must be stored out of the sight and reach of children and pets. For disposal, unused or expired tablets should not be flushed down the toilet or poured into drains. Official guidelines recommend utilizing authorized drug take-back programs or disposing of the product in the household trash after mixing it with an undesirable substance.